JPRN-UMIN000007708
Recruiting
未知
Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow - - Evaluation of the efficacy of Symbicort turbuhaler that target patients with bronchial ashtma complicated by COPD and bronchial asthma - Evaluation of diurnal variation in peak flow
Department of respirology, graduate School of Medicine, Chiba University0 sites100 target enrollmentApril 10, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- bronchial asthma complicated by COPD and bronchial ashtma
- Sponsor
- Department of respirology, graduate School of Medicine, Chiba University
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •\>patient wiht an infection refractory to any antibiotics, or deep\-seated mycoses \>hitory of hypersensitivity to test drug
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month randomised, double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma. - AHEADThis is a Phase IIIB study to be performed in adult and adolescent asthmatic patients.Classification code 10003553EUCTR2004-004905-11-ESAstraZeneca AB2,309
Active, not recruiting
Not Applicable
Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month randomised, double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma. - AHEADThis is a Phase IIIB study to be performed in adult and adolescent asthmatic patients.Classification code 10003553EUCTR2004-004905-11-DEAstraZeneca AB2,300
Completed
Phase 3
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanChronic Obstructive Pulmonary DiseaseNCT01070784AstraZeneca328
Completed
Phase 3
Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic PatientsAsthmaNCT00252785AstraZeneca340
Active, not recruiting
Not Applicable
A comparison of the efficacy of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 microg, one inhalation twice a day plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomised, open, parallel-group, multicentre, 26 weeks study - MONOEUCTR2004-000679-32-FIAstraZeneca Oy1,900